Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Psoriatic Arthritis Treatment Market: By Drug Class, TNF Alfa Inhibitors, Corticosteroids, Interleukin Inhibitors, PDE4 Inhibitors, Others), By Disease Indication, By Route of Administration, By Distribution Channel, and Region Forecast 2019-2030
Psoriatic Arthritis Treatment Market size was valued at US$ 7.61 billion in 2023 and is poised to grow at a CAGR of 9.5% from 2024-2030. Psoriatic Arthritis is a form of arthritis developed in people affected by psoriasis. It causes affected joints to become swollen, stiff, and painful. Most of the people affected by psoriasis are first and later diagnosed with psoriatic arthritis. Approximately 15-25% of people with psoriasis can develop psoriatic arthritis. Symptoms associated with psoriatic arthritis include swollen joints, low back pain, nail pitting, conjunctivitis, and foot pain among others.
Psoriatic arthritis is a type of arthritis that affects some people who suffer from psoriasis, a dyskinesia ailment that causes red patches with silvery scales. The majority of people first acquire psoriasis before being diagnosed with psoriatic arthritis. Joint difficulties, on the other hand, might occasionally start before skin patches emerge. When the immune system attacks healthy cells and tissue, this disease develops. Inflammation of the joints, as well as an overproduction of skin cells, are caused by an aberrant immunological response.
Study Period
2024-2030Base Year
2023CAGR
9.5%Largest Market
EuropeFastest Growing Market
North-America
Increase in the prevalence of psoriasis results to rise in number of psoriatic arthritis patients is a key factor enhance the revenue of psoriatic arthritis market. Moreover, rise in R&D for the innovation of newer products, pipeline drugs under various stages of clinical trials, frequent product launchings by the market players, and increase in the awareness about psoriatic arthritis treatment among the healthcare professionals are expected to drive the global psoriatic treatment market over the forecast years. However, stringent regulations for the product approval, high cost of treatment, entry of biosimilars into market, and lack of standardization tools for diagnosis and treatment are restrain the growth of the market.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 7.61 billion |
Market CAGR |
9.5% |
By Drug Class |
|
By Disease Condition |
|
By Route Administration |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The global psoriatic arthritis psa treatments market size was valued at US$ 7.61 billion in 2023 and is projected to grow at a CAGR of 9.5% from 2024 to 2030.
The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The market key players are: Bristol Myers Squibb Company (U.S.), Hoffmann La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Amgen, Inc. (U.S.), Hohnson & Johnson Services, Inc. (U.S.)
1. Executive Summary |
2. Global Psoriatic Arthritis Psa Treatments Market Introduction |
2.1.Global Psoriatic Arthritis Psa Treatments Market - Taxonomy |
2.2.Global Psoriatic Arthritis Psa Treatments Market - Definitions |
2.2.1.Drug Class |
2.2.2.Disease Condition |
2.2.3.Route Administration |
2.2.4.Distribution Channel |
2.2.5.Region |
3. Global Psoriatic Arthritis Psa Treatments Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Psoriatic Arthritis Psa Treatments Market Analysis, 2019-2023 and Forecast 2024-2030 |
4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Psoriatic Arthritis Psa Treatments Market By Drug Class, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
5.1. Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. TNF Alfa Inhibitors |
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Corticosteroids |
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Interleukin Inhibitors |
5.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. PDE4 Inhibitors |
5.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Global Psoriatic Arthritis Psa Treatments Market By Disease Condition, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
6.1. Mild |
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Moderate |
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Severe |
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Psoriatic Arthritis Psa Treatments Market By Route Administration, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
7.1. Oral |
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Parenteral |
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Topical |
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Psoriatic Arthritis Psa Treatments Market By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Psoriatic Arthritis Psa Treatments Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10. North America Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
10.1. Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
10.1.2.TNF Alfa Inhibitors |
10.1.3.Corticosteroids |
10.1.4.Interleukin Inhibitors |
10.1.5.PDE4 Inhibitors |
10.1.6.Others |
10.2. Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Mild |
10.2.2.Moderate |
10.2.3.Severe |
10.3. Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Oral |
10.3.2.Parenteral |
10.3.3.Topical |
10.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospital Pharmacies |
10.4.2.Retail Pharmacies |
10.4.3.Online Pharmacies |
10.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11. Europe Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
11.1.2.TNF Alfa Inhibitors |
11.1.3.Corticosteroids |
11.1.4.Interleukin Inhibitors |
11.1.5.PDE4 Inhibitors |
11.1.6.Others |
11.2. Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Mild |
11.2.2.Moderate |
11.2.3.Severe |
11.3. Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Oral |
11.3.2.Parenteral |
11.3.3.Topical |
11.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospital Pharmacies |
11.4.2.Retail Pharmacies |
11.4.3.Online Pharmacies |
11.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
11.5.6.Rest of EU |
12. Asia Pacific (APAC) Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
12.1.2.TNF Alfa Inhibitors |
12.1.3.Corticosteroids |
12.1.4.Interleukin Inhibitors |
12.1.5.PDE4 Inhibitors |
12.1.6.Others |
12.2. Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Mild |
12.2.2.Moderate |
12.2.3.Severe |
12.3. Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Oral |
12.3.2.Parenteral |
12.3.3.Topical |
12.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospital Pharmacies |
12.4.2.Retail Pharmacies |
12.4.3.Online Pharmacies |
12.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13. Middle East and Africa (MEA) Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
13.1.2.TNF Alfa Inhibitors |
13.1.3.Corticosteroids |
13.1.4.Interleukin Inhibitors |
13.1.5.PDE4 Inhibitors |
13.1.6.Others |
13.2. Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Mild |
13.2.2.Moderate |
13.2.3.Severe |
13.3. Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Oral |
13.3.2.Parenteral |
13.3.3.Topical |
13.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospital Pharmacies |
13.4.2.Retail Pharmacies |
13.4.3.Online Pharmacies |
13.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14. Latin America Psoriatic Arthritis Psa Treatments Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
14.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
14.1.2.TNF Alfa Inhibitors |
14.1.3.Corticosteroids |
14.1.4.Interleukin Inhibitors |
14.1.5.PDE4 Inhibitors |
14.1.6.Others |
14.2. Disease Condition Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Mild |
14.2.2.Moderate |
14.2.3.Severe |
14.3. Route Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Oral |
14.3.2.Parenteral |
14.3.3.Topical |
14.4. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospital Pharmacies |
14.4.2.Retail Pharmacies |
14.4.3.Online Pharmacies |
14.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Bristol-Myers Squibb Company (U.S.) |
15.2.2.Hoffmann La Roche Ltd. (Switzerland) |
15.2.3.Novartis AG (Switzerland) |
15.2.4.Amgen, Inc. (U.S.) |
15.2.5.Hohnson & Johnson Services, Inc. (U.S.) |
15.2.6.AbbVie Inc. (U.S.) |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players